title: Experience with imipenem in internal medicine--a postmarketing surveillance study.
abstract: Imipenem was registered for clinical use in Germany in 1985. It is recommended for initial treatment in either severe nosocomial infections or infections in ICU or immunocompromised patients. In this study, we evaluated 1,215 patients who were prescribed imipenem at our Zentrum der Inneren Medizin-a major tertiary care university hospital-over a 6 year period. 650 of 1,215 patients (53.5%) had rapidly fatal disease; and the main indication for imipenem was pneumonia and fever of unknown origin. 56.2% received 500 mg imipenem t.i.d., 40.4% 500 mg b.i.d., 0.9% 1000 mg b.i.d.; and 2.5% 1000 mg t.i.d. Average duration of treatment was 11 days. Lower dose (500 mg b.i.d.) was used in patients with renal insufficiency; highest dose was used in severe infections or infections caused by moderately sensitive organisms. Imipenem was used as a single initial antibacterial agent in the majority of the patients. Success was seen in 80% of the episodes, irrespective of the dosage used; 89% at 500 mg b.i.d., 74% at 500 mg t.i.d., 77% at 1,000 mg b.i.d.; and 69% at 1,000 mg t.i.d. We observed the highest favourable response (91.5%) in the episodes treated initially with imipenem monotherapy. Overall, imipenem was well tolerated. The majority of the patients with untoward effects was on multiple-drug regimens. The most frequent untoward event observed involved the gastrointestinal tract.
authors.affiliation: Medizinische Klinik III/Infektiologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt/Main, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Schaumann
authors.forename: C
authors.initials: C
authors.lastname: Albinger
authors.forename: H V
authors.initials: HV
authors.lastname: Olesch
authors.forename: W
authors.initials: W
authors.lastname: Stille
authors.forename: P M
authors.initials: PM
authors.lastname: Shah
mesh_terms: D000328:Adult; D000368:Aged; D015377:Cilastatin / Q000009:adverse effects / Q000627:therapeutic use; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005858:Germany; D006801:Humans; D015378:Imipenem / Q000009:adverse effects / Q000627:therapeutic use; D007239:Infections / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing
chemical_list: D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination